Sentences with phrase «government and industry regulatory»

Background includes extensive project work on scientific initiatives designed to clean up waste, mitigate environmental risk, minimize future pollution, improve environmental sustainability, and meet government and industry regulatory standards.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

In fact, a recent study in the American Journal of Public Health finds that the EPA «has moved away from the public interest and explicitly favored the interests of the regulated industries,» and is on the slippery slope to what scholars term «regulatory capture,» in which a government agency makes rules in the interest of an industry it's supposed to regulate rather than the public.

This U.S. venture capital company invests in numerous business segments, including its foray into RegTech thanks to Managing Partner Wayne Kimmel's decision to put money into KIND Financial, a regulatory and compliance platform for the cannabis industry and for the government to monitor those businesses.

Like many in the industry, Russell doesn't know when the program will get regulatory approval, but in the meantime he'd like the government to give business owners a tax deduction on EI and CPP for contributions they make to a group RSP.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

In short, Canada's staggeringly powerful oil industry wants «oversight» (their word) of political, civil service, and regulatory institutions in both the Alberta and federal governments.

Mark H. Goldberg and Associates provides a full range of consulting to the telecommunications industry, including: business planning, strategic advisory services, carrier relations, regulatory and government relations, network design, RFP evaluations, project management and operations reviews.

Investments in fast - growing industries like the technology and healthcare sectors (which have historically been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments.

Investments in fast - growing industries like the technology and health care sectors (which have historically been volatile) could result in increased price fluctuation, especially over the short term, due to the rapid pace of product change and development and changes in government regulation of companies emphasizing scientific or technological advancement or regulatory approval for new drugs and medical instruments.

The nature of religious television in America can be seen to be a function of the interaction of four main players; changes over the past decades have come about because of changes in the relative power and relationships of the four following players: (1) the regulatory agencies of the federal government, which, through the legislative process, provide the structure within which interaction inside the television industry takes place; (2) the television industry, primarily network and local station managements, which control the airwaves within the legislated structure; (3) the viewing public, which selects what it is that will be watched; and (4) the religious broadcasters who provide the material for broadcasts.

The Australian and New Zealand Government's Food Regulation Policy Options Paper on caffeine acknowledges the Beverages Council's Energy Drink Industry Commitment document and notes that «while these self - regulatory codes only formally apply to members of those organisations, their existence and application across the market may also affect the behaviour of non-members that are aware of them.»

«Despite its successes, the regulatory model for ESCAS is complex and imposes costs of over $ 17.6 million a year on government and the industry.

As senior vice president of government affairs for ABA, McGreevy is responsible for shaping advocacy strategies for the beverage industry and representing the interests of ABA members before lawmakers and regulatory bodies.

The GMA leadership team includes foremost scientific, health, government and regulatory experts across the consumer packaged goods industry.

The Association also serves as liaison between the industry, government and the public, and provides a unified voice in legislative and regulatory matters.

The Australian Beverages Council also recognises its responsibility to provide extensive communication to Governments, community groups, the media, and consumers with respect to the industry's views on regulatory matters, legislation, and public policy, dietary guidelines, health claims, and front - of - pack labelling are just a few examples of specifics that are proactively addressed to these audiences within these fields.

We need to address issues such as agile regulatory systems, government support for the MTP industry and its businesses, a focus on innovation and commercial viability as well as education and reskilling of the workforce.

Policy Reform participation in the development of industry submissions, responses to government discussion papers, and the regulatory review processes.

Dairy products enjoy strong support within government, and the industry has sponsored many studies, and many dietary societies, in order to remain relevant — see Marion Nestle's Food Politics for a study of scientific and regulatory capture by the food industry.

One of the risks gaining attention from industry, governments, regulatory bodies and consumer organisations is food fraud conducted for economic gain.

The Summit will bring together small business owners, financial institutions, support industries, and government stakeholders to help facilitate access to capital, reduce regulatory barriers, and grow employment and investment at our smallest — but most critical — places of business.

If you want to learn more about the job market and prospective employers, you'll find links to information about current research, clinical trials, and patents; industry news; trade, regulatory, and government bodies; and a list of publications that you can access for free to keep up - to - date with industry trends.

Francis says employers in industry, the nonprofit sector, and government are clamoring for employees with advanced training in science and mathematics and professional skills in areas such as management, marketing, communication, regulatory affairs, intellectual property, and business ethics.

The aim is for the findings to be taken forward by government, the IT sector and wider industry to help create the legal / regulatory framework and technical capabilities needed to release the full commercial potential of the «big data» revolution.

Expert panelists from government, private industry, science and medicine provided invaluable information on the legal and regulatory challenges faced by professionals practicing in areas affected by personalized medicine, including labeling issues, laboratory developed tests, IVD approval and reimbursement and PGx - tailored drugs and companion diagnostics.

The stakeholders participating in the Roundtable — including scientists, physicians, the pharmaceutical and insurance industries, government, patient groups, and others — discussed a case study, which was used as a springboard to confront issues from the highly technical to the economic, ethical, and regulatory that will need to be addressed if personalized medicine is to be incorporated into the mainstream of health care.

Specifically, the new center will bring together a centralized group of all constituents within this area creating a multi-disciplinary interest group whereby industry, big pharma, physicians, scientists, government and regulatory agencies as well as other stakeholders can convene to share ideas, develop education offerings and advance the utilization of radionuclide therapy.

These risks and uncertainties include, among others, those relating to our ability to obtain financing and to form collaborative relationships, uncertainty regarding potential future deterioration in the market for auction rate securities which could result in additional permanent impairment charges, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

These risks and uncertainties include, among others, those relating to technology and product development, integration of acquired businesses, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission.

These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going concern, the outcome of the review of the continued listing of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic products, the level of third party reimbursement for our products, risks related to preclinical and clinical development of pharmaceutical products, including the identification of compounds and the completion of clinical trials, our ability to form collaborative relationships, the effect of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our products, dependence on collaborative relationships, the effect of competitive products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

The all - day meeting showcased the work of more than 100 experts from academia, federal and regulatory agencies, government research agencies, pharmaceutical and biotech industry, and patient advocacy community who have worked together over the past several months to prepare draft consensus recommendations on how to address the regulatory issues around HIV cure research.

With 2016 underway, members of the herp industry across the United States face new opportunities, new legislative and regulatory attacks on businesses, and new challenges to reptile and amphibian ownership at all levels of government.

And we are excited to bring our legislative and regulatory experience and expertise to bear on behalf of the entire industry as we work with the Pet Leadership Council on a broad array of government affairs topiAnd we are excited to bring our legislative and regulatory experience and expertise to bear on behalf of the entire industry as we work with the Pet Leadership Council on a broad array of government affairs topiand regulatory experience and expertise to bear on behalf of the entire industry as we work with the Pet Leadership Council on a broad array of government affairs topiand expertise to bear on behalf of the entire industry as we work with the Pet Leadership Council on a broad array of government affairs topics.

Humane Canada supports stringent regulatory controls over genetic engineering of animals and continues to promote knowledgeable international debate on this issue by government, industry, the animal welfare movement and the public.

Humane Canada supports stringent regulatory controls on the biotechnology industry and urgently seeks national and international debate by government, industry, animal protection organizations and the public on the ethical, environmental, economic and social implications of genetic engineering.

A problem that we, as an industry, need to talk about is the fact that government affairs work — legislative and regulatory representation — is a necessary element of doing business in this country.

This is the legislative and regulatory environment that your pet industry government affairs team at the Pet Industry Joint Advisory Council (PIJAC) navigates evindustry government affairs team at the Pet Industry Joint Advisory Council (PIJAC) navigates evIndustry Joint Advisory Council (PIJAC) navigates every day.

The mission of the American Horse Council is to promote and protect the equine industry by representing its interests in Congress and in federal regulatory agencies on national issues of importance; to unify the equine industry by informing industry members of regulations and pending legislation, and by serving as a forum for all member organizations and individuals; and to advise and inform government and the industry itself of the equine industry's important role in the United States economy.

«Self - regulation, such as that done by the Entertainment Software Rating Board for video games, is an effective way for companies to modify their behavior to protect consumers where the government could or should not act... The electronic game industry continues to have the strongest self - regulatory code and enforcement of restrictions on marketing, advertising and selling mature - rated games to younger audiences.»

I find it interesting that a particular organization might be indicted for supposedly being funded by the fossil fuel industry when so many organizations and studies fueling the global warming alarmism are funded by governments and not suprisingly endorse MORE government (in the form of regulations, regulatory agencies, taxes, fees, etc...) as a supposed «solution» to the problem.

Dozens of other recent studies reached similar conclusions — including peer - reviewed case studies and research by academics, government and industry, as well as state and federal regulatory reviews.

The project is being supported through a # 100,000 (US$ 132,358.5) grant from the government in support of national industry regulator Ofgem which is currently researching the potential for blockchain and peer - to - peer trading platforms within its so - called «regulatory sandbox».

We launched the inaugural 40 Under 40 in 2015 to celebrate Midwest Energy News «fifth anniversary and received hundreds of nominations of Midwest - based leaders and innovators from all sectors — industry, government, regulatory, business, academic, and advocacy.

Governments, in collaboration with industry, can play a determinant role in developing policy and regulatory mechanisms that unlock the private finance necessary for such a boost in investment.

However, the real question is whether the U.S. government is taking a regulatory approach of any kind and imposing emissions regulations on industry — not necessarily cap and trade.

With CO2 Solutions» efficient, cost effective and green carbon capture technology, the Company looks forward to supporting worldwide efforts by industry and governments to efficiently meet these regulatory requirements for emissions reductions.

Similarly, in Uruguay, modest but strategic climate finance investment by UNDP and the GEF in electricity market regulatory reform, combined with ambitious targets from the Uruguayan government, has spurred rapid growth in the country's wind industry and helped to leverage billions of dollars of investment.

Obama: I have always been in favor of an «all of the above» climate policy, including a carbon price with cap and trade, crippling EPA regulatory restrictions on the coal plus oil and gas industries, fewer incentives for exploratory drilling, no further drilling on government lands, no Keystone pipeline, more taxes on the rich, etc..